New pill could ease heavy periods from fibroids
NCT ID NCT07402369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called CMS-D002 for women with uterine fibroids who have heavy menstrual bleeding. About 120 women aged 18-50 will take either the drug or a placebo daily for 12 weeks. The goal is to see if the drug can reduce bleeding to normal levels and shrink fibroids.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CMS-D002 capsule
- What this could lead to
- If successful, this could offer a new non-surgical option to reduce heavy bleeding and improve quality of life for women with uterine fibroids.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1.Non-menopausal females aged 18-50 years. * 2\. Body Mass Index (BMI) ≥ 18 kg/m². * 3\. Participant was diagnosed with uterine fibroids by ultrasound at the time of screening, and has one or more fibroids with a diameter of at least 2 cm (longest diameter). * 4\. Participant's menstrual cycle was ≥ 21 days and ≤ 35 days for the three consecutive months prior to screening, and the menstrual period was ≤ 14 days. * 5\. Menorrhagia due to uterine fibroids. * 6\. Agrees to use the contraceptive method specified in the protocol throughout the entire study period (from signing the informed consent form to 6 months after administration of the investigational drug). Exclusion Criteria: * 1\. Pregnant or breastfeeding female * 2\. History of childbirth within 6 months prior to screening * 3\. Excessive menstrual bleeding due to other causes or unknown reasons * 4\. Suffering from a severe coagulation disorder (e.g., hemophilia or von Willebrand disease) * 5\. Underwent myomectomy, endometrial ablation, uterine artery embolization, or magnetic resonance-guided focused ultrasound (MRgFUS)/high-intensity focused ultrasound (HIFUS) ablation within 6 months prior to screening * 6\. Underwent endometrial ablation within one year prior to screening * 7\. Severe infection, severe trauma, or major surgery within the 6 months prior to screening. * 8\. History of malignant tumors within the 5 years prior to screening (excluding cured skin cancer, basal cell carcinoma, and other localized malignant tumors). * 9\. Current or past (within 1 year) history of alcohol or drug abuse (including analgesic abuse). * 10\. Currently participating in other research projects and having used the investigational drug/treatment within 12 weeks prior to administration.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Uterine fibroids with menorrhagia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China